Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy.
Non-muscle invasive bladder cancer (NMIBC)
adjuvant bladder therapy
anxiety
quality of life (QoL)
short form survey (SF-36)/State-Trait Anxiety Inventory (STAI)
Journal
Bladder cancer (Amsterdam, Netherlands)
ISSN: 2352-3735
Titre abrégé: Bladder Cancer
Pays: Netherlands
ID NLM: 101668567
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
11
2020
accepted:
15
05
2021
medline:
31
8
2021
pubmed:
31
8
2021
entrez:
12
7
2024
Statut:
epublish
Résumé
Bladder cancer (BC) is one of the most common malignancies (4.5%of all newly diagnosed cases worldwide). Most of the new BC cases are diagnosed as non-muscle invasive BC (NMIBC), needing continuous follow up after primary endoscopic therapy. Adjuvant bladder therapy with chemo- or immuno- agents, apart from the initial diagnosis, the strict surveillance program and the risk of recurrence, may have a major impact on the patients' physical and mental health. We evaluated anxiety and quality of life (QoL) in patients who underwent surgery for NMIBC and followed a bladder instillation programme. This is a prospective analysis of patients with histopathologically confirmed NMIBCs. Eligible were all adult patients with a single or multiple NMIBCs who underwent a transurethral tumor resection and followed a therapy with either BCG or Epirubicin instillations. The SF-36 questionnaire Physical and Mental health aspects were used for QoL assessment. Similarly, the STAI-Y was introduced for the state (STAI-Y1) and trait anxiety (STAI-Y2) evaluation. 117 eligible patients were screened, with 108 entering finally the study; 9 patients were excluded due to disease recurrence. 17 patients (15.7%) received Epirubicin (Ta-T1, Low Grade tumors), whereas 91 patients (84.3%) received BCG (T1, High Grade). Regarding SF-36 Physical a 6 months decrease was followed by an improvement at 12 months ( Patient QoL and anxiety improved during follow up. Still, further larger scale studies are required to support our findings.
Sections du résumé
BACKGROUND
BACKGROUND
Bladder cancer (BC) is one of the most common malignancies (4.5%of all newly diagnosed cases worldwide). Most of the new BC cases are diagnosed as non-muscle invasive BC (NMIBC), needing continuous follow up after primary endoscopic therapy. Adjuvant bladder therapy with chemo- or immuno- agents, apart from the initial diagnosis, the strict surveillance program and the risk of recurrence, may have a major impact on the patients' physical and mental health.
OBJECTIVE
OBJECTIVE
We evaluated anxiety and quality of life (QoL) in patients who underwent surgery for NMIBC and followed a bladder instillation programme.
METHODS
METHODS
This is a prospective analysis of patients with histopathologically confirmed NMIBCs. Eligible were all adult patients with a single or multiple NMIBCs who underwent a transurethral tumor resection and followed a therapy with either BCG or Epirubicin instillations. The SF-36 questionnaire Physical and Mental health aspects were used for QoL assessment. Similarly, the STAI-Y was introduced for the state (STAI-Y1) and trait anxiety (STAI-Y2) evaluation.
RESULTS
RESULTS
117 eligible patients were screened, with 108 entering finally the study; 9 patients were excluded due to disease recurrence. 17 patients (15.7%) received Epirubicin (Ta-T1, Low Grade tumors), whereas 91 patients (84.3%) received BCG (T1, High Grade). Regarding SF-36 Physical a 6 months decrease was followed by an improvement at 12 months (
CONCLUSION
CONCLUSIONS
Patient QoL and anxiety improved during follow up. Still, further larger scale studies are required to support our findings.
Identifiants
pubmed: 38993613
doi: 10.3233/BLC-201524
pii: BLC201524
pmc: PMC11181705
doi:
Types de publication
Journal Article
Langues
eng
Pagination
297-306Informations de copyright
© 2021 – The authors. Published by IOS Press.
Déclaration de conflit d'intérêts
Alexandros Vaioulis has no conflict of interest to report. Konstantinos Bonotis has no conflict of interest to report. Konstantinos Perivoliotis has no conflict of interest to report. Yiannis Kiouvrekis has no conflict of interest to report. Stavros Gravas has no conflict of interest to report. Vasilios Tzortzis has no conflict of interest to report. Anastasios Karatzas has no conflict of interest to report.